FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 12/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.
As of the end of December 2023 we identify the following current VC trends in Europe:
- In 2023, overall Life Sciences funding has reached EUR 8,949m
- Biotech received 42% of the total investment volume (+1% compared to the previous month)
- Oncology dominates as the top indication in Biotech
- Freya Biosciences (Denmark) has the highest transaction volume of EUR 35m in December, followed by Laza Medical (Switzerland) EUR 33m and Eligo Biosciences (France) EUR 30m
- The EIC Fund (vehicle of the European Innovation Council, Belgium) dominates the Top 5 Investors (by deal volume), followed by Jeito (France) and Forbion (Netherlands)
- Top 5 Deals exceed EUR 130m each, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To access the full report, please click here.
By Mathias Klozenbücher, Johannes Link and Marco Buonafede-Bennardo.